On March 23, 2022, the MyRealWorld™ MG (MRW MG) study expanded to include Denmark in its list of study countries. This means that the digital real-world evidence study, which has been ongoing since December 2019, now operates across nine countries: the US, Canada, Japan, Germany, the UK, France, Italy, Spain, and most recently, Denmark.
The international reach of MRW MG is noteworthy. Myasthenia Gravis is a rare and chronic disease, with an estimated incidence range of 0.3 to 2.8 per 100,000 people worldwide¹. The fact that participants in MRW MG can enter data about their condition and its management on their own device, at a time and place that is convenient to them, means that the potential study population is considerably wider when compared with traditional clinical trials – a fact which is especially meaningful in the context of a rare disease.

About MyRealWorld MG™
MyRealWorld™ MG (MRW MG) is sponsored by argenx.
MRW MG is an international observational longitudinal study designed with patients and clinical experts to understand the real-world impact of living with MG. Visit our dedicated study page to find out more, or click here if you are a researcher who is interested in accessing the MRW MG dataset to gain insight into MG and improve patient care.

About Vitaccess
We are innovators in real-world evidence research. We connect biopharma to patients and caregivers on any device, worldwide – harnessing our scientific expertise and cutting-edge digital technology to generate real-time, real-world insights through the powerful combination of our Vitaccess Real™ digital platform and expert consultative insight.
Born in Oxford, we have team presence across Europe and the US. We are health economists, researchers, eClinical health experts, data scientists, software developers, linguists, and medical writers, all committed to insightful digital research.
We are passionate about inclusivity and open ways of working – we believe the more voices and views we listen to, the better we can make real progress, together.
Click here to have a chat about how we can support your real-world evidence generation needs.

¹Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. The Lancet Regional Health – Western Pacific 5 2020; 5:100063. doi:10.1016/j.lanwpc.2020.100063

Skip to content